Citius Pharmaceuticals, Inc. Income Statement
CTXR|3 years of annual SEC 10-K data (FY2011-FY2013)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 3 fiscal years. All figures from audited SEC 10-K filings.
Citius Pharmaceuticals, Inc. reported $0 in revenue and $1M in net loss for FY2013.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2013 | FY2012 | FY2011 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| SG&A Expense | $690.4K | $4.1K | $12.2K |
| R&D Expense | $492.1K | - | - |
| Operating Income | -$1.2M | -$19.6K | -$25.6K |
| Interest Expense | $105.5K | $3.1K | $704 |
| Income Tax | $0 | $0 | $0 |
| Net Income | -$1.3M | -$22.0K | -$26.3K |
| EPS (Basic) | $0.00 | $0.00 | - |
| EPS (Diluted) | $0.00 | $0.00 | $0.00 |
| Shares Outstanding | 18.0M | 18.0M | 18.0M |